Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mulders

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
BJU International|January 8, 2010
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanismsPeter Mulders
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancersFred Saad, Peter Mulders
Current Opinion in Urology|March 20, 2021
Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximabTim van Oostenbrugge, Peter Mulders
Future Oncology (London, England)|August 12, 2009
Vitespen: a preclinical and clinical reviewChristopher G Wood, Peter Mulders
The Urologic Clinics of North America|September 5, 2003
Tumor antigens and markers in renal cell carcinomaPeter Mulders, Ivar Bleumer, Egbert Oosterwijk
Anticancer Research|February 9, 2013
Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohortMaciej Salagierski, Peter Mulders, Jack A Schalken
BJU International|May 26, 2012
Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized careAxel Bex, Martin Gore, Peter Mulders, et al.
The Journal of ECT|January 9, 2024
Structural Changes in Depressed Patients Directly After Treatment With Electroconvulsive Therapy and 3 Months LaterStevie Jaarsveld, Peter Mulders, Indira Tendolkar, et al.
Elife|July 4, 2019
Inter-individual differences in human brain structure and morphology link to variation in demographics and behaviorAlberto Llera, Thomas Wolfers, Peter Mulders, et al.
Immunotherapy|May 4, 2013
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinomaStijn Muselaers, Peter Mulders, Egbert Oosterwijk, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
BJU International|January 8, 2010
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanismsPeter Mulders
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancersFred Saad, Peter Mulders
Current Opinion in Urology|March 20, 2021
Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximabTim van Oostenbrugge, Peter Mulders
Future Oncology (London, England)|August 12, 2009
Vitespen: a preclinical and clinical reviewChristopher G Wood, Peter Mulders
The Urologic Clinics of North America|September 5, 2003
Tumor antigens and markers in renal cell carcinomaPeter Mulders, Ivar Bleumer, Egbert Oosterwijk
Anticancer Research|February 9, 2013
Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohortMaciej Salagierski, Peter Mulders, Jack A Schalken
BJU International|May 26, 2012
Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized careAxel Bex, Martin Gore, Peter Mulders, et al.
The Journal of ECT|January 9, 2024
Structural Changes in Depressed Patients Directly After Treatment With Electroconvulsive Therapy and 3 Months LaterStevie Jaarsveld, Peter Mulders, Indira Tendolkar, et al.
Elife|July 4, 2019
Inter-individual differences in human brain structure and morphology link to variation in demographics and behaviorAlberto Llera, Thomas Wolfers, Peter Mulders, et al.
Immunotherapy|May 4, 2013
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinomaStijn Muselaers, Peter Mulders, Egbert Oosterwijk, et al.
Pageof 7